Paik et al. [81] conducted an open-label, phase 2 study with the administration of tepotinib (at a dose of 500 mg) once daily for eligible advanced-stage NSCLC patients with a confirmed MET Exon 14 skipping mutation. This evidence concerns the gene MET and non-small cell lung carcinoma.